In the treatment of Primary Immunodeficiency (PI) in
adults and pediatric patients 2 years of age and older.confident. complete. cutaquig.

Introducing a Subcutaneous Immune Globulin Therapy That Delivers Innovative Service and Support

Learn More

Safe and effective PI treatment

Zero serious bacterial infections in clinical studies in adults and children.1-3

See the results

Discover the
IgCares patient support program

Join the program and explore the unique benefits for cutaquig patients.

Get greater support

Transitioning to

Making the transition is simple and straightforward to manage.1

Switch now

Resources to get started right

Receive guidance on co-pay assistance and reimbursement matters.

Learn more

Questions about cutaquig?

Find helpful answers to common questions about cutaquig and PI.

Learn more

Cutaquig Full Prescribing Information. Paramus, NJ: Octapharma; rev October 2021.Kobayashi RH, Gupta S, Melamed I, et al. Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies. Front Immunol. 2019;10(40):1-12.Kobayashi RH, Mandujano JF, Rehman SM, et al. Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm]). Immunotherapy. 2021;13(10):813 -824.